Sarepta Therapeutics (NASDAQ:SRPT) Rating Lowered to Hold at BidaskClub

Sarepta Therapeutics (NASDAQ:SRPT) was downgraded by analysts at BidaskClub from a “buy” rating to a “hold” rating in a research note issued to investors on Tuesday, December 19th.

Other equities analysts have also recently issued reports about the company. Oppenheimer reiterated a “buy” rating on shares of Sarepta Therapeutics in a research report on Monday, September 25th. SunTrust Banks reiterated a “buy” rating and set a $56.00 price target on shares of Sarepta Therapeutics in a research report on Thursday, September 7th. Needham & Company LLC reiterated a “buy” rating and set a $75.00 price target on shares of Sarepta Therapeutics in a research report on Wednesday, September 6th. Nomura reiterated a “buy” rating and set a $84.00 price target on shares of Sarepta Therapeutics in a research report on Tuesday, September 5th. Finally, Instinet reiterated a “buy” rating and set a $84.00 price target on shares of Sarepta Therapeutics in a research report on Monday, October 2nd. Two investment analysts have rated the stock with a sell rating, five have assigned a hold rating and seventeen have assigned a buy rating to the company’s stock. Sarepta Therapeutics currently has an average rating of “Buy” and an average target price of $63.88.

Shares of Sarepta Therapeutics (SRPT) traded up $2.53 during mid-day trading on Tuesday, hitting $61.52. The stock had a trading volume of 2,217,656 shares, compared to its average volume of 1,700,000. Sarepta Therapeutics has a one year low of $26.26 and a one year high of $61.89. The firm has a market cap of $3,980.00, a PE ratio of -30.16 and a beta of 1.37. The company has a current ratio of 10.44, a quick ratio of 9.52 and a debt-to-equity ratio of 0.04.

Sarepta Therapeutics (NASDAQ:SRPT) last issued its quarterly earnings results on Wednesday, October 25th. The biotechnology company reported ($0.20) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.86) by $0.66. Sarepta Therapeutics had a negative return on equity of 51.72% and a negative net margin of 112.08%. The company had revenue of $45.95 million for the quarter, compared to analysts’ expectations of $41.29 million. During the same period last year, the firm earned ($0.95) EPS. sell-side analysts predict that Sarepta Therapeutics will post -3.07 EPS for the current year.

In other Sarepta Therapeutics news, CEO Douglas S. Ingram bought 38,138 shares of the firm’s stock in a transaction dated Wednesday, November 8th. The stock was acquired at an average price of $52.44 per share, with a total value of $1,999,956.72. Following the completion of the transaction, the chief executive officer now directly owns 420,196 shares in the company, valued at approximately $22,035,078.24. The purchase was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this link. Also, SVP Shamim Ruff sold 10,000 shares of Sarepta Therapeutics stock in a transaction on Monday, November 6th. The shares were sold at an average price of $55.00, for a total value of $550,000.00. Following the sale, the senior vice president now directly owns 37,045 shares of the company’s stock, valued at approximately $2,037,475. The disclosure for this sale can be found here. Company insiders own 9.60% of the company’s stock.

A number of institutional investors and hedge funds have recently added to or reduced their stakes in SRPT. Russell Investments Group Ltd. boosted its position in Sarepta Therapeutics by 96.4% during the second quarter. Russell Investments Group Ltd. now owns 75,170 shares of the biotechnology company’s stock valued at $2,534,000 after purchasing an additional 36,897 shares during the last quarter. Pictet Asset Management Ltd. boosted its position in Sarepta Therapeutics by 5.2% during the second quarter. Pictet Asset Management Ltd. now owns 71,100 shares of the biotechnology company’s stock valued at $2,122,000 after purchasing an additional 3,500 shares during the last quarter. Canada Pension Plan Investment Board acquired a new stake in Sarepta Therapeutics during the second quarter valued at $630,000. Schwab Charles Investment Management Inc. boosted its position in Sarepta Therapeutics by 4.9% during the second quarter. Schwab Charles Investment Management Inc. now owns 215,190 shares of the biotechnology company’s stock valued at $7,255,000 after purchasing an additional 10,003 shares during the last quarter. Finally, First Trust Advisors LP boosted its position in Sarepta Therapeutics by 74.9% during the second quarter. First Trust Advisors LP now owns 31,094 shares of the biotechnology company’s stock valued at $1,048,000 after purchasing an additional 13,316 shares during the last quarter. 82.02% of the stock is owned by hedge funds and other institutional investors.

ILLEGAL ACTIVITY NOTICE: “Sarepta Therapeutics (NASDAQ:SRPT) Rating Lowered to Hold at BidaskClub” was first posted by The Ledger Gazette and is the property of of The Ledger Gazette. If you are accessing this piece on another publication, it was copied illegally and republished in violation of international copyright laws. The correct version of this piece can be viewed at https://ledgergazette.com/2018/01/13/sarepta-therapeutics-srpt-rating-lowered-to-hold-at-bidaskclub.html.

Sarepta Therapeutics Company Profile

Sarepta Therapeutics, Inc is a biopharmaceutical company. The Company focuses on the discovery and development of ribose nucleic acid (RNA)-targeted therapeutics for the treatment of rare neuromuscular diseases. It operates through discovering, developing, manufacturing and delivering therapies to patients with Duchenne muscular dystrophy (DMD).

Analyst Recommendations for Sarepta Therapeutics (NASDAQ:SRPT)

Receive News & Ratings for Sarepta Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Sarepta Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply